| 07.05 22:50 | dpa-AFX: Myriad Genetics Inc. Q1 Loss Decreases, beats estimates |
| 07.05 22:44 | dpa-AFX: *MYRIAD GENETICS Q1 LOSS/SHARE $0.29 VS. LOSS $0.67 YEAR AGO |
| 07.05 22:44 | dpa-AFX: *MYRIAD GENETICS Q1 TESTING REVENUE $202.2 MLN VS. $181.2 MLN LAST YEAR |
| 07.05 21:02 | dpa-AFX: Myriad Genetics Q1 24 Earnings Conference Call At 4:30 PM ET |
| 27.02 22:17 | dpa-AFX: *MYRIAD GENETICS Q4 NET LOSS $31.2 MLN VS. LOSS $42.3 MLN PRIOR YEAR |
| 27.02 22:17 | dpa-AFX: *MYRIAD GENETICS Q4 LOSS/SHARE $0.36 VS. LOSS $0.52 YEAR AGO |
| 27.02 22:17 | dpa-AFX: *MYRIAD GENETICS Q4 TESTING REVENUE $196.6 MLN VS. $177.8 MLN LAST YEAR |
| 27.02 22:11 | dpa-AFX: Myriad Genetics Inc. Q4 Earnings Summary |
| 19.12 11:33 | dpa-AFX: *WELLS FARGO REINITIATES MYRIAD GENETICS WITH 'EQUAL WEIGHT' - PRICE TARGET 20 USD |
| 19.12 11:33 | dpa-AFX: *WELLS FARGO NIMMT MYRIAD GENETICS MIT 'EQUAL WEIGHT' WIEDER AUF - ZIEL 20 USD |
| 06.11 22:57 | dpa-AFX: Myriad Genetics Inc. Q3 Loss Increases, but beats estimates |
| 06.11 21:00 | dpa-AFX: Myriad Genetics Q3 23 Earnings Conference Call At 4:30 PM ET |
| 26.10 15:09 | dpa-AFX: QIAGEN, Myriad Genetics To Develop Companion Diagnostic Tests In Field Of Cancer |
| 26.10 14:47 | dpa-AFX: *QIAGEN AND MYRIAD GENETICS PARTNER TO ADVANCE COMPANION DIAGNOSTICS DEVELOPMENT FOR CANCER |
| 03.08 23:28 | dpa-AFX: Myriad Genetics Inc. Q2 Earnings Summary |
| 03.08 22:54 | dpa-AFX: *MYRIAD GENETICS Q2 LOSS/SHARE $1.42 VS. LOSS $0.18 YEAR AGO |
|
|
